PriceSensitive

Imugene (ASX:IMU) generates income of $5.34m in H1 FY22

ASX News, Health Care
ASX:IMU      MCAP $16.16M
28 February 2022 13:32 (AEDT)
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Source: Imugene

Imugene (IMU) has recorded income of $5.34 million for the half year ended December 31, 2021, up from the $4.11 million in the prior corresponding period.

The company posted a net loss for the six-month period of $14.8 million, up from a loss of about $6 million previously, largely due to the significant increase in clinical trial and research activities undertaken.

As a result of its successful share placement, share purchase plan and exercise of options during the latest reported half year, Imugene holds cash reserves of $118.4 million.

Operations

HER-Vaxx study

In November, Imugene entered a clinical trial supply agreement with Merck KGaA, Darmstadt and Pfizer to evaluate the safety and efficacy of its HER-Vaxx immunotherapy in combination with chemotherapy.

HER-Vaxx is designed to treat tumours that over-express the HER-2/neu receptor such as breast, lung, gastric, ovarian and pancreatic cancers.

The study’s primary endpoint is pathologic complete response and secondary endpoints include safety and biomarker evaluation.

Japan patent

In September, Imugene received a notice of grant from the Japanese Patent Office for HER-Vaxx.

The patent is titled “A vaccine Composition and Uses Thereof” and protects the method of composition and method of use of HER-Vaxx until 2036.

A patent was then granted in China under the same title and same terms as Japan.

PD1-Vaxx

Imugene used the half to recruit patients for its first-in-human, phase one, multi-centre, dose escalation study of PD1-Vaxx in patients with non-small cell lung cancer.

The primary goal is to determine the safety and optimal dose of PD1-Vaxx with patients either receiving 10, 50 or 100 micrograms.

PD1-Vaxx was designed to treat tumours such as lung cancer by producing an anti-cancer effect.

Clinical results indicate that it is showing early signs of an immune response in patients with antibodies related to PD1-Vaxx evident in assays.

IMU shares were steady at 23.5 cents at 1:29 pm AEDT.

Related News